Drug Trial Radar · NCT01379989
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
617
Actual
Start
Jun 2011
Primary completion
Dec 17, 2020
Study completion Dec 17, 2020
Sponsor
- Lead sponsor
- Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- PharmaMar; Averion International Corporation
- First posted
- Jun 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.
Conditions
- Ovarian Cancer
Interventions
CarboplatinDrug
Carboplatin AUC 5
Pegylated Lipoxomal Doxorubicin (PLD)Drug
PLD 30 mg/m² i.v.
TrabectedinDrug
trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: This outcome measure will be assess approximately 4.5-5 years after the last patient enrolled
Locations
132 sites in 11 countries. Site status is shown where the registry gives one.
Medizinische Universitat Graz
Graz, Austria
Univ. Klinik Frauenheilkunde AKH
Vienna, Austria
Krankenhaus Der Barmherzigen Brueder
Graz, AT, Austria
Univ. Clinic for Gynaecology and Obstetrics - Medical University of Innsbruck
Innsbruck, AT, Austria
AZ Maria Middelares
Ghent, Belgium
UZ Gent
Ghent, Belgium
Imeldaziekenhuis
Bonheiden, BE, Belgium
AZ Klina
Brasschaat, BE, Belgium
Antwerp University Hospital
Edegem, BE, Belgium
UZ Leuven
Leuven, BE, Belgium
CMSE Clinique et Maternité Sainte-Elisabeth
Namur, BE, Belgium
Az Damiaan
Ostend, BE, Belgium
Centrum Voor Oncologie
Turnhout, BE, Belgium
Centre Hospitalier Peltzer La Tourelle (CHPLT)
Verviers, BE, Belgium
CHU Dinant Godinne / UCL Namur
Yvoir, BE, Belgium
Odense University Hospital
Odense, DK, Denmark
Kuopio University Hospital - Kuopio
Kuopio, Finland
Oulu University Hospital
Oulu, Finland
Tampere University Hospital
Tampere, FI, Finland
Staedtisches Klinikum Brandenburg
Brandenburg an der Havel, Germany
Universitatsfrauenklinik Dusseldorf
Düsseldorf, Germany
Kliniken Essen Mitte Evang. Huyssens Stiftung
Essen, Germany
University Medical Center Hamburg
Hamburg, Germany
Universitaetsklinikum Jena
Jena, Germany
Klinikum Leverkusen gGmbH
Leverkusen, Germany
Studienzentrum Onkologie
Ravensburg, Germany
UFK am Klinikum Suedstadt Rostock
Rostock, Germany
Onkologische Schwerpunktpraxis
Speyer, Germany
Charite Universitaetsmedizin
Berlin, DE, Germany
Ev. Waldkrankenhaus Spandau
Berlin, DE, Germany
Praxis Dr. med. Jörg Schilling
Berlin, DE, Germany
Praxisklinik Krebsheilkunde für Frauen
Berlin, DE, Germany
Vivantes Netzwerk für Gesundheit GmbH
Berlin, DE, Germany
University Hospital Dresden
Dresden, DE, Germany
Dr. med. Georg Heinrich Schwerpunktpraxis für Gynäkologische Onkologie
Fürstenwalde, DE, Germany
Kath. Marienkrankenhaus
Hamburg, DE, Germany
Universitäts - Frauenklinik -Tübingen
Heidelberg, DE, Germany
Helios Klinikum Krefeld
Krefeld, DE, Germany
"Universitätsklinikum Schleswig-Holstein
Lübeck, DE, Germany
AOU Materdomini
Catanzaro, Italy
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.